Biosynthesis in Nervous Tissue
The formation of gamma-aminobutyric acid occurs directly within neurons. The direct and sole precursor of this neurotransmitter is glutamic acid (glutamate).
The process is a decarboxylation reaction (removal of a $CO_2$ molecule from the amino acid). This reaction is catalyzed by a specific enzyme, glutamate decarboxylase (GAD). For this enzyme to function properly, the coenzyme pyridoxal phosphate (PLP), which is the active form of vitamin $B_6$, is strictly required. Any deficiency in vitamin $B_6$ inevitably impairs the synthesis rate of the inhibitory neurotransmitter, leading to a predominance of excitatory processes in the nervous system.
Inactivation and the GABA Shunt
Once the neurotransmitter has fulfilled its physiological function, it must be inactivated. In biochemistry, this process is known as the GABA shunt. It proceeds in two consecutive steps, ensuring not only the clearance of the molecule but also the return of its carbon skeleton to cellular energy metabolism.
- Transamination. The molecule interacts with $\alpha$-ketoglutarate ($\alpha$-KG). The amino group is transferred to the keto acid, resulting in the formation of succinic semialdehyde and a new molecule of glutamate. The reaction is catalyzed by the enzyme GABA transaminase, which, like the synthesis enzyme, is strictly dependent on the PLP ($B_6$) coenzyme.
- Oxidation. Succinic semialdehyde undergoes oxidation in the presence of succinic semialdehyde dehydrogenase. Ultimately, this yields succinate, which directly enters the tricarboxylic acid (TCA) cycle for further energy production.
Clinical Application and the Blood-Brain Barrier Challenge
In medical practice, GABA-based medications (such as Aminalone or Gamalon) belong to the group of nootropics. They are prescribed for pathological conditions characterized by acute, uncontrolled excitation of the cerebral cortex—such as epilepsy, traumatic brain injury, and stroke, where the delicate balance between inhibition and excitation is disrupted.
The beneficial effects of these drugs include:
- Improvement of overall brain tissue metabolism.
- Enhanced glucose utilization by nerve cells.
- Increased neuronal respiratory activity (a potent antihypoxic effect).
An important pharmacokinetic nuance: the GABA molecule itself crosses the blood-brain barrier (BBB) extremely poorly. Therefore, the clinical effect of exogenous (externally administered) acid is most commonly attributed to an indirect improvement in cerebral blood flow and peripheral metabolism. To directly target CNS receptors, pharmacologists have synthesized special derivatives that easily cross the BBB—such as phenibut or picamilon.